As we have previously identified givinostat as a promising anti-leukemic agent for CRLF2r BCP-ALL cases [27], we sought to evaluate its synergistic capability with other compounds FDA/EMA-approved or in preclinical studies included in a HTP drug screening library of 174 compounds [26]. The gene discussed is OPN1SW; the disease is acute lymphoblastic leukemia.